Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05420467 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study for the Adjuvant Treatment of Breast Cancer

StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Changed Sponsor changed: Second Affiliated Hospital, School of Medicine, Zhejiang University to Second Affiliated Hospital, Zhejiang University, School of Medicine
  2. Study title shortened, about 3 wordsv3
  3. Interventions: Albumin-Bound Paclitaxel, cyclophosphamide (Drug), Albumin-Bound Paclitaxel,Carboplatin，Trastuzumab，Pertuzumab (Drug), Albumin-Bound… to Carboplatin (Drug), Cyclophosphamide (Drug), Cyclophosphamide (Drug), Cyclophosphamide (Drug), Docetaxel (Drug), Docetaxel (Drug)…
    • Eligibility criteria shortened, about 14 words
    • Study description shortened, about 21 words
    • Study title shortened, about 7 words
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Studies on postoperative adjuvant albumin paclitaxel in domestic breast cancer patients are less reported, especially in large samples, and more studies focus more on the safety and tolerability of albumin paclitaxel use. Head-to-head studies of white violet and docetaxel are not supported by data at this time, but some studies have shown that docetaxel-induced long-term Other adverse effects such as myelosuppression, hepatotoxicity and hypersensitivity reactions can have a serious impact on quality of life. Therefore, this study aims to analyse the efficacy and safety of albumin paclitaxel and docetaxel in the adjuvant treatment of breast cancer in a large randomized controlled trial, and to further analyse the efficacy and safety of albumin paclitaxel in combination with chemotherapy for postoperative breast cancer in different subtypes of breast cancer patients, in order to obtain more realistic data and provide new treatment options for breast cancer patients.
Trial Details
NCT Number NCT05420467
Lead Sponsor Second Affiliated Hospital, Zhejiang University, School of Medicine
Conditions
(from sponsor)		 Breast Cancer
Related terms Breast Neoplasms
Enrollment 2,413 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov